New Hope for Saving Diabetic Foot from Amputation

Dec. 24, 2010 - PRLog -- During ICMS (International Cellular Medicine Society www.cellmedicinesociety.org),  Annual International Congress on Regenerative and Cell Based Medicine Conference held on November 12, 2010 in Las Vegas, Nevada, it was announced that a patient with complications of diabetes gangrene recovered from foot ulcer through stem cell therapy.

Patient, Sun Rae Cho (age 72 from Chungbuk, South Korea) who suffered from complications of diabetes for 17 years, received stem cell treatment through leading biopharmaceutical company specialized in adult stem cell therapeutics, RNL Bio Co., Ltd (Dr. Jeong Chan Ra, Chairman of RNL Bio www.rnl.co.kr). Cho experienced remarkable effects such as healed ulcers and improvement of tingling sensation on feet last September.

According to the press release, after Cho was diagnosed with diabetes mellitus in 1993, he had to wear an insulin pump in suffering day to day. Due to these complications, Cho’s five toes began to swell and change color since last May. There became increasingly large areas of pus and deep wounds on his feet. He was told by doctors that his legs would have to be amputated. There was no other option for Cho’s condition.

Cho resorted to having surgery for his leg amputation at a local hospital in Seoul, Korea last September. Then, he was referred to RNL Bio to seek treatment with his preserved stem cells for treatment on September 15, 2010. He traveled to China and Japan for infusions of 300 million stem cells on each foot.

Just 10 days after Cho’s stem cell injection, there was 70-80% improvement in pus and wounds; an improvement of 90% was exhibited 20 days later. As the wounds began to heal, the pain and tingling was no longer evident.

In the case of RNL Bio released by ICMS, Dr. Ra stated, "In cases like Cho’s condition, patients can gain hope through stem cell therapy rather than facing the worst case scenario of having to get one’s leg amputated. There is continuous hope until the day comes where stem cell therapy will be available to anyone worldwide.”

# # #

RNL Bio is a premier biotechnology company focused on the research and development of adult derived stem cell therapies. RNL has conducted two Phase II clinical trials for Buerger’s Disease as well as Osteoarthritis and one phase I trial for spinal cord injury. RNL is a publically traded company listed in the Korean Stock Exchange (Code 003190) and is expanding its operations throughout the world.